
ENGN Stock Forecast & Price Target
ENGN Analyst Ratings
Bulls say
enGene Holdings Inc. demonstrates a positive outlook due to its strong clinical results and regulatory progress, particularly with the RMAT designation for its lead candidate, detalimogene, which positions the company to capture a significant share in the non-muscle invasive bladder cancer market. The company’s strategic advancements have led to a six-month complete response (CR) rate aligned with best-in-class therapies while leveraging the non-viral nature of its delivery platform, enhancing its adoption potential. Additionally, the rise in research and development expenses reflects commitment to pivotal studies, further supported by an upward revision of the discounted cash flow-derived price target, indicating growing confidence in the company's future revenue generation capabilities.
Bears say
enGene Holdings Inc. faces a negative outlook primarily due to disappointing performance in the ongoing LEGEND trial for Detalimogene, coupled with unexpected safety issues that may hinder its development. The changing regulatory landscape for approvals in non-muscle invasive bladder cancer (NMIBC) and the emergence of unforeseen competition add to the company's challenges, particularly as clinical response rates (CR) have fallen below prior expectations. Additionally, higher than anticipated capital requirements may necessitate further equity financing, raising dilution risks for existing shareholders and potentially impacting the company's overall financial health.
This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.
ENGN Analyst Forecast & Price Prediction
Start investing in ENGN
Order type
Buy in
Order amount
Est. shares
0 shares